Quarterly Activities Report and 4C – period ended 31 March 2024
LTR Pharma has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31 March 2024. Key highlights from this period include: Pivotal clinical study of SPONTAN® fully recruited and completed dosing of all participants. SPONTAN achieved key manufacturing validation and first commercial batch production. SPONTAN is designed […]
SPONTAN® pivotal clinical study completes recruitment and dosing
LTR Pharma has today announced that all patients recruited for its pivotal bioequivalence clinical study of SPONTAN® nasal spray have now received their second and final dose, completing the recruitment and dosing stage of the clinical study. The Study is evaluating the relative bioavailability of SPONTAN, a novel and proprietary PDE5 nasal spray treatment compared […]
Ausbiz | Interview with Lee Rodne
This week, LTR Pharma’s Executive Chairman, Lee Rodne, spoke with Juliette Saly from ausbiz to discuss the Company’s progress in the advancement of rapid treatment for Erectile Dysfunction (ED), SPONTAN®, including the commencement of recruitment for its pivotal bioequivalence study. Take a look:
First patients dosed for SPONTAN® bioequivalence clinical study
LTR Pharma is pleased to announce the commencement of patient dosing in the Company’s pivotal bioequivalence clinical study of SPONTAN® nasal spray. The clinical study will assess the relative bioavailability of SPONTAN, a novel and proprietary PDE5 nasal spray treatment for ED. This first-in-kind nasal spray will be compared to oral administration of Vardenafil, a […]
ASX:LTP Half Year Financial Report
LTR Pharma has today released its Half Year Financial Report for the period ended 31 December 2023. This has been a defining period for the Company, marked by a successful ASX debut on 11 December 2023, and rapid progress towards our pivotal bioequivalence study. Key highlights include: Successfully completed an oversubscribed IPO. The Company listed […]
Biotech Dispatch | LTR Pharma says patient recruitment commences for pivotal clinical study
Biotech Dispatch has reported LTR Pharma’s announcement that patient recruitment has commenced for its pivotal clinical study of SPONTAN nasal spray. Click here to read the article.
Stockhead | ASX stocks striving to inject youthfulness into an aging world population
LTR Pharma’s innovative nasal spray for erectile dysfunction, SPONTAN is featured in a Stockhead article by Nadine McGrath titled “ASX stocks striving to inject youthfulness into an aging world population” The article highlights the investment opportunities in ASX-listed companies that are addressing issues associated with longevity and the ageing population. “LTP executive director Lee Rodne […]
Clinical Trials Arena | LTR Pharma begins recruitment in study of nasal spray for ED
News that LTR Pharma’s pivotal clinical trial is set to begin has been reported in Clinical Trials Arena. An excerpt: “The trial will take place in Sydney, Australia, in partnership with Southern Star Research and Scientia Clinical Research. It will be conducted under the supervision of staff from Scientia Clinical Research, while Southern Star Research will […]
The Market Bull | LTR Pharma Initiates SPONTAN® Nasal Spray Trial for Erectile Dysfunction
LTR Pharma’s announcement that its has commenced recruitment for its bioequivalence study has been featured in this article by Tylah Tully in The Market Bull – Daily Stock News.. Click here to read the article.
BNNBreaking | Revolutionary Nasal Spray for Erectile Dysfunction: SPONTAN® Clinical Trial Begins
BNN Breaking has published the news that LTR Pharma has initiated enrolment of patients for its pivotal bioequivalence clinical trial of the nasal spray treatment, SPONTAN®. An excerpt: “The implications of SPONTAN®’s success extend far beyond the realm of erectile dysfunction. A positive outcome from the trial could set the stage for regulatory approval from heavyweights […]
Stockhead | LTR Pharma firms up study for erectile dysfunction with patient recruitment
LTR Pharma has been featured in Stockhead following the announcement that patient recruitment for its pivotal clinical study of SPONTAN® has opened. An excerpt: “The global ED market is forecast to increase to US$5.94 billion by 2028, growing at a CAGR of 7.1%. With such strong demand for effective ED treatments, LTP hit the Aussie bourse […]
Patient Recruitment Commences for SPONTAN® Pivotal Clinical Study
LTR Pharma has today announced patient recruitment has commenced for its pivotal bioequivalence clinical study for SPONTAN®, a fast-acting, on-demand Nasal Spray treatment for Erectile Dysfunction (ED). The Study will assess the relative bioavailability of Vardenafil following administration of SPONTAN nasal spray, when compared to oral delivery of Vardenafil tablets – a widely used PDE5 […]
BBN Breaking | LTR Pharma, AFT Pharmaceuticals Make Major Strides in US Healthcare Market
International news network BBN Breaking has reported news of LTR Pharma’s completion of manufacturing validation for SPONTAN this week. Describing SPONTAN as a “game-changer in Erectile Dysfunction treatment”, the article highlights the significance of meeting all the prerequisites for a pivotal FDA clinical study as the Company prepares to commence patient recruitment for the bioequivalence study. […]
The Australian | ASX Health Stocks: LTP is recruiting for patients to try its erection spray
LTR Pharma’s announcement that it has achieved manufacturing validation for SPONTAN has been covered by The Australian Business Review, in an article titled “ASX Health Stocks: LTP is recruiting for patients to try its erection spray.” Click here to read the article.
SPONTAN® Achieves Key Manufacturing Validation For Pivotal Clinical Study
LTR Pharma has today announced it has achieved manufacturing validation for its upcoming bioequivalence clinical study for its lead product, SPONTAN®. The Company, in conjunction with its Contract Manufacturing Organisation (CMO), has now successfully met the essential criteria for a pivotal FDA clinical study – including stability testing, quality control checks, product purity and packaging […]
The Australian | ‘Pharma and hydrogen take top IPO status in a tough year’
LTR Pharma has been named among the top performing IPOs on the Australian market this year in an article by business reporter Eli Greenblat in The Australian newspaper this week. Reflecting on the sluggish market for new listings globally, he wrote: “Among the best performers among the IPOs was LTR Pharma, which is working on […]
Proactive | LTR Pharma announces company is now trading on the ASX under the ticker LTP
LTR Pharma Executive Chairman Lee Rodne joined Steve Darling from Proactive to share the exciting news that the company has initiated trading on the Australian Securities Exchange under the ticker symbol LTP. Take a look:
The Courier Mail, The Australian | ‘Brisbane drug company gets the rise on Viagra’
News Corp (The Courier Mail, The Australian) Business Journalist, Glen Norris, has published an article in today’s business section titled ‘Brisbane drug company gets the rise on Viagra’. It examines the PDE5 inhibitor market and why SPONTAN® may be a preferred treatment, as a potentially fast-acting intranasal spray solution. Click here to read the full […]
Ausbiz | LTR Pharma ASX Debut
LTR Pharma (ASX:LTP) Independent Non-Executive Director, Dr Julian Chick, was interviewed on Ausbiz to discuss the Company’s ASX debut. Take a look:
Biotech Daily | 11 December 2023
LTR Pharma has again been featured in Biotech Daily in an article titled, ‘LTR Up 105% On Spontan Erectile Dysfunction IPO’. Read the full report.